SCHEMBL29495185

SCHEMBL29495185

C[C@H](O)C1CCC(NC(=O)c2nc(-n3ccnc3)nc3ccsc23)CC1

nearest known ligand 0.85

Predicted protein targets (top 1)

geneUniProtsupporting neighboursconfidence
CD38 P28907 20/20 0.85

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22936508 1.00 CD38 (0.85) CD38
SCHEMBL29696405 1.00 CD38 (0.85) CD38
SCHEMBL22936497 1.00 CD38 (0.85) CD38
SCHEMBL22947089 0.92 CD38 (1.00) CD38
SCHEMBL22947088 0.92 CD38 (1.00) CD38
SCHEMBL22936148 0.87 CD38 (0.74) CD38
SCHEMBL29494917 0.86 CD38 (0.82) CD38
SCHEMBL22947055 0.86 CD38 (0.82) CD38
SCHEMBL29495209 0.86 CD38 (0.73) CD38
SCHEMBL22946904 0.85 CD38 (0.75) CD38

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-119431323-A Heterobicyclic amides as CD38 inhibitors 贝林格尔·英格海姆国际有限公司 2025-02-14 CN claimed
EP-4003980-A1 HETEROBICYCLIC AMIDES AS INHIBITORS OF CD38 Ribon Therapeutics Inc. (US) 2022-06-01 EP claimed
CN-119431323-A Heterobicyclic amides as CD38 inhibitors 贝林格尔·英格海姆国际有限公司 2025-02-14 CN disclosed
CN-114423753-B Heterobicyclic amides as CD38 inhibitors 里邦医疗公司 2024-09-17 CN disclosed
EP-4003980-A1 HETEROBICYCLIC AMIDES AS INHIBITORS OF CD38 Ribon Therapeutics Inc. (US) 2022-06-01 EP disclosed
CN-114423753-A Heterobicyclic amides as CD38 inhibitors 里邦医疗公司 2022-04-29 CN disclosed